Comparision of three different doses of nalbuphine which is added to to Intrathecal hyperbaric bupivacaine in patients undergoing knee joint surgeries.

Comparision of three different doses of nalbuphine as adjuvant to intrathecal hyperbaric bupivacaine in knee joint surgeries.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/08/020916

Enrollment

120

Registered

2019-08-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M239- Unspecified internal derangement of knee

Interventions

Intervention1: Nalbuphine: It is an Opioid analgesic,Dose-0.4mg added as an adjuvant to intrathecal hyperbaric bupivacaine. Intervention2: Nalbuphine: It is an opioid analgesic.Dose-0.8mg added as an

Eligibility

Inclusion criteria

Inclusion criteria: American society of anesthesiologists (ASA) Physical status I and II,patient posted for surgery of knee joint.

Exclusion criteria

Exclusion criteria: ASA PH III and IV,Height 30,Contraindication to spinal anesthesia,H/o adverse reactions to opioids,pregnancy.

Design outcomes

Primary

Measure	Time frame
To determine the optimum dose of nalbuphine with maximum analgesic and minimal side-effects.Timepoint: Asessed every 15mins postoperatively till the patient receives first dose of rescue analgesia.	—

Secondary

Measure	Time frame
Duration of onset and regression of snsory and motor blockade.Timepoint: sennsory and motor status will be checked every 2 minutes after spinal injection for first 10 minutes,every 5 minutes for next 30 minutes,and 15mins till regression.	—

Countries

India

Contacts

Public ContactDrSaswati Das

Kalinga Institute of Medical Sciences

das.saswati12@gmail.com9910760328

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026